Trial Profile
A Phase 1, Placebo-controlled, Randomized, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of An Adjuvanted Clostridium Difficile Vaccine Administered As A 3-dose Regimen In Healthy Adults Aged 50 To 85 Years
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Sep 2021
Price :
$35
*
At a glance
- Drugs PF 6425090 (Primary) ; QS 21; Toxoids
- Indications Clostridium difficile infections
- Focus Adverse reactions
- Acronyms QS-21 study
- Sponsors Pfizer
- 03 Sep 2021 Results assessing the safety and immunogenicity data from two clinical studies (QS-21 study NCT02052726 and toxoid-alone study NCT02117570) that evaluated the use of alternative formulations of this vaccine candidate in healthy adults, published in the Vaccine.
- 09 Jun 2015 Planned End Date changed from 1 Jul 2015 to 1 May 2015 as per ClinicalTrials.gov record.
- 09 Jun 2015 Planned primary completion date changed from 1 Jul 2015 to 1 May 2015 as per ClinicalTrials.gov record.